Is Tesamorelin the same as growth hormone?

No. Tesamorelin is a GHRH analog that prompts the pituitary to release the body's own growth hormone in pulses. No exogenous GH is supplied. This makes the mechanism fundamentally different from HGH preparations.

What is Tesamorelin approved for?

The regulatory approval concerns the reduction of visceral adipose tissue in HIV-associated lipodystrophy. Applications beyond that, such as liver fat or cognition, are the subject of research and are not covered by the approval.

How strong is the effect on visceral fat?

In Phase III studies, visceral adipose tissue fell by about 18 percent over 26 weeks versus placebo at a dose of 2 mg daily. After discontinuation the fat tends to return, so the effect is tied to continued use.

What does the data say about the liver?

A randomized twelve-month study in people with HIV and fatty liver showed reduced liver fat and slowed fibrosis progression. That is relevant in the context of MASLD but applies first to the studied population.

Is there evidence for cognitive effects?

There is an early finding of improved executive function and verbal memory in older adults, mediated by GH and IGF-1. The sample is small and the duration short. This is a hypothesis for further research, not a proven effect against cognitive decline.

Tesamorelin: Visceral Belly Fat, Liver Fat (MASLD) and a New Cognition Finding

Tesamorelin holds a special position among the growth hormone secretagogues: it is one of the few peptides in this field with full regulatory approval. As a GHRH analog (a stabilized analogue of the body's own Growth-Hormone-Releasing Hormone), it was developed clinically and approved under the name Egrifta against visceral adipose tissue in HIV-associated lipodystrophy. It is precisely this clinical depth that makes it interesting to researchers studying the GH/IGF-1 system.

This overview frames three research threads: the robust data on visceral fat, the growing literature on liver fat and MASLD (formerly NAFLD), and a more recent finding on cognitive function that should be read with greater caution.

TL;DR: What Sets Tesamorelin Apart

Mechanism: GHRH analog, stimulates the body's own pulsatile GH release rather than supplying exogenous GH. Visceral fat: roughly 18 percent reduction of visceral adipose tissue over 26 weeks in Phase III studies (2 mg/day). Liver: randomized data show reduced liver fat and slowed fibrosis progression in MASLD in the HIV context. Cognition: an early study found improved executive function and verbal memory in older adults, mediated by GH and IGF-1. Small sample, not endpoint proof. Status: approved for a specific indication, anything beyond that is research.

Mechanism of Action: Stimulate the GH Axis, Do Not Replace It

The decisive difference from exogenous growth hormone is that Tesamorelin prompts the body's own pituitary to release GH in physiological pulses. It binds at the GHRH receptor and thereby raises GH and, downstream, IGF-1, without completely overriding the feedback loop. The idea behind it: a signal that stays closer to natural pulsatility, rather than a flat, permanently elevated GH level.

This mechanic explains why Tesamorelin is considered separately from pure GH preparations in research. It shares the GH axis with other secretagogues we carry, but differs in half-life and depth of clinical data.

Tesamorelingrowth

Modified GHRH analog for lipodystrophy and metabolic liver research

Visceral Fat: the Best-Documented Endpoint

The strongest dataset concerns visceral adipose tissue (VAT), the deep belly fat around the organs that is metabolically far more active and riskier than subcutaneous fat. In the pivotal Phase III studies, Tesamorelin 2 mg daily over 26 weeks led to a reduction of visceral adipose tissue of about 18 percent versus placebo.

Important for a clean framing: this data comes primarily from the population with HIV-associated lipodystrophy, for which the agent is approved. Transferability to other contexts is the subject of ongoing research and is not covered by the same evidence.

Methodology Note

The primary endpoint of the approval studies was the percentage change in visceral adipose tissue, measured by CT. The reduction correlated with the rise in IGF-1. After discontinuation, visceral fat tends to return, so the effect is tied to continued use.

Liver Fat and MASLD: the Most Important Extension

Because visceral fat and liver fat accumulation are closely linked, one research thread has shifted to the liver. A randomized, double-blind, multicenter study examined Tesamorelin 2 mg daily over twelve months in people with HIV and non-alcoholic fatty liver disease. The result: reduced liver fat content and lower fibrosis progression, accompanied by reduced hepatic inflammatory gene expression and increased oxidative phosphorylation pathways (Stanley et al., PMC6981288).

Against the backdrop of the new nomenclature (MASLD and MASH replacing NAFLD and NASH), this finding is relevant because it shows a mechanism that goes beyond mere fat mass: less inflammation, more mitochondrial activity. Here too the context restriction of the studied population applies.

Cognition: an Interesting but Early Finding

The most speculative thread concerns cognitive function. A study in older adults, including people with mild cognitive impairment, found improvements in executive function and verbal memory over 20 weeks. The effect was explained via the neurotrophic properties of GH and IGF-1.

Important: Limitation of the Cognition Data

This is an early finding with a small sample and short duration. It does not prove efficacy against dementia or age-related cognitive decline. Treat it as a hypothesis for further research, not an established effect. Larger, independent and longer studies are lacking.

Framing Against Other GH Secretagogues

Tesamorelin is not the only peptide targeting the GH axis. For research planning, it is worth looking at the related compounds in the catalog, which differ in half-life, receptor profile and data situation.

Sermorelingrowth

GHRH(1-29) analog for physiological growth hormone stimulation research

Ipamorelingrowth

Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.

Sermorelin is the shorter, older GHRH fragment, Ipamorelin a selective GHRP (ghrelin mimetic). Tesamorelin stands out through its approval and the depth of its clinical data. Anyone studying the GH/IGF-1 system systematically would sensibly document which signaling principle is being addressed in each case.

Practical Consequences for Lab Work

1. Keep indication and research cleanly separated. The approval applies to a specific population. Any other question (general visceral adiposity, MASLD outside of HIV, cognition) is research and should be documented as such.

2. Keep IGF-1 in mind as an accompanying marker. The fat and liver effects correlate with the IGF-1 rise. In a research design, IGF-1 is an obvious parameter to track over time.

3. Plan for reversibility. The effect on visceral fat is tied to continued use. That is relevant for study design and interpretation.

Frequently Asked Questions

For research purposes only. This article summarizes published literature. It is not medical advice and is not an endorsement of any particular protocol.